Treatment with CMP and FSK—potentially involving alterations in LAT1 and lamin B1 (Fig. 5A–C; See Supplementary Figs. S6 and S7)—in combination with olaparib, led to greater reductions in survival across all ovarian cancer cells tested at the lowest concentrations of olaparib (Fig. 6). This evidence concerns the gene LMNB1 and ovarian cancer.